Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of “Moderate Buy” from Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been given an average rating of “Moderate Buy” by the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $22.83.

A number of equities research analysts have commented on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. HC Wainwright began coverage on shares of Neumora Therapeutics in a report on Tuesday, October 1st. They issued a “buy” rating and a $30.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a report on Friday. Finally, Mizuho started coverage on shares of Neumora Therapeutics in a research report on Monday, July 8th. They set an “outperform” rating and a $20.00 target price for the company.

Neumora Therapeutics Trading Down 2.8 %

NMRA opened at $16.49 on Friday. The company’s 50 day moving average is $12.73 and its 200-day moving average is $11.36. The company has a market cap of $2.63 billion and a P/E ratio of -6.44. Neumora Therapeutics has a 1-year low of $8.33 and a 1-year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). On average, equities analysts forecast that Neumora Therapeutics will post -1.48 EPS for the current year.

Insider Buying and Selling at Neumora Therapeutics

In other news, CFO Joshua Pinto sold 31,642 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $11.78, for a total transaction of $372,742.76. Following the completion of the sale, the chief financial officer now owns 154,658 shares in the company, valued at $1,821,871.24. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Joshua Pinto sold 31,642 shares of Neumora Therapeutics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the transaction, the chief financial officer now owns 154,658 shares in the company, valued at $1,821,871.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the sale, the director now directly owns 20,100 shares in the company, valued at $342,303. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 110,538 shares of company stock worth $1,390,513 in the last quarter. 26.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD purchased a new stake in shares of Neumora Therapeutics in the 1st quarter valued at about $10,354,000. Callan Capital LLC lifted its holdings in shares of Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after acquiring an additional 456,207 shares during the last quarter. Rhumbline Advisers boosted its position in Neumora Therapeutics by 488.3% during the second quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock valued at $1,015,000 after buying an additional 85,706 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Neumora Therapeutics by 79.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company’s stock valued at $1,099,000 after acquiring an additional 49,527 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Neumora Therapeutics in the second quarter worth approximately $566,000. 47.65% of the stock is owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.